Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Allergen Research Raises USD80 Million in Series B Financing 11
Allergen Research Raises US$17 Million In Series A Financing 13
Partnerships 14
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 14
Aimmune Therapeutics Enters Into Agreement With Nestle Health Science 15
Equity Offering 16
Aimmune Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD202.4 Million 16
Aimmune Therapeutics Raises USD145 Million in Private Placement of Shares 18
Aimmune Therapeutics Raises USD184 Million in IPO 19
Aimmune Therapeutics Inc – Key Competitors 20
Aimmune Therapeutics Inc – Key Employees 21
Aimmune Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Strategy And Business Planning 23
Jun 07, 2017: CoreRx and Aimmune Therapeutics Joint Expansion to Create Pharmaceutical Jobs and Increase the Base of Scientific Capabilities in the Tampa Bay Area 23
Financial Announcements 24
Aug 08, 2018: Aimmune Therapeutics announces second quarter 2018 financial results 24
May 08, 2018: Aimmune Therapeutics Announces First Quarter 2018 Financial Results 25
Mar 12, 2018: Aimmune Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 26
Nov 06, 2017: Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 28
Aug 08, 2017: Aimmune Therapeutics Announces Second Quarter 2017 Financial Results 30
May 08, 2017: Aimmune Therapeutics Announces First Quarter 2017 Financial Results 32
Mar 15, 2017: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results 33
Corporate Communications 35
Feb 14, 2018: Aimmune Therapeutics Names George du Toit and Wayne Shreffler to Scientific Advisory Board 35
Apr 13, 2017: Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer 36
Product News 37
06/07/2017: Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy 37
Clinical Trials 38
Mar 04, 2018: Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO 38
Feb 27, 2018: Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results at the AAAAI-WAO Joint Congress 40
Feb 20, 2018: Aimmune Therapeutics Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy 41
Feb 12, 2018: Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress 44
Jan 10, 2018: Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy 45
Jan 08, 2018: Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy 46
Nov 20, 2017: Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1 47
Oct 31, 2017: Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial 48
Oct 19, 2017: Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings 50
Aug 08, 2017: Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy 51
Jul 05, 2017: Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy 52
Jun 20, 2017: Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress 53
Jun 15, 2017: Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017 54
Jun 12, 2017: Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy 55
May 11, 2017: Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy 56
Mar 06, 2017: Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 57
Feb 27, 2017: Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 59
Feb 16, 2017: Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Allergen Research Raises USD80 Million in Series B Financing 11
Allergen Research Raises US$17 Million In Series A Financing 13
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 14
Aimmune Therapeutics Enters Into Agreement With Nestle Health Science 15
Aimmune Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD202.4 Million 16
Aimmune Therapeutics Raises USD145 Million in Private Placement of Shares 18
Aimmune Therapeutics Raises USD184 Million in IPO 19
Aimmune Therapeutics Inc, Key Competitors 20
Aimmune Therapeutics Inc, Key Employees 21
Aimmune Therapeutics Inc, Other Locations 22
Aimmune Therapeutics Inc, Subsidiaries 22
List of Figures
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9